drugset / Trial / NCT00731445
Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II is studying the side effect and best dose of Z-208 for patients with advanced hepatocellular carcinoma
Timeline
- Start
- 2008-07
- Primary completion
- 2012-01
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Z-208 | Unknown | 4 mg | Oral |
| Subject | Z-208 | Unknown | 8 mg | Oral |
| Subject | Z-208 | Unknown | 12 mg | Oral |
| Subject | Z-208 | Unknown | 16 mg | Oral |